Oyster Therapeutics, a London drug developer working on treatments for Alzheimer's disease, raised $60m in a Series A round led by 4BIO Capital, it announced on 10 November 2026. The company changed its name from Kesmalea Therapeutics at the same time.
Eli Lilly and Company joined as a new investor, along with Actium Group, CE-Ventures and TOHO Ventures, which is managed by Global Brain. Existing shareholders Syncona, Oxford Science Enterprises, Mission BioCapital and MGB Ventures also put in money. No valuation was disclosed.
The press release describes the financing as a Series A, while Pharmaceutical Technology reported it as a Series A-2. The company has not disclosed how much it raised before this round.
“This financing accelerates our progress towards the clinic and enables us to validate a new approach to targeted protein degradation, or TPD, that solves some of its major limitations through the use of smaller molecules.”Rob Johnson, Chief Executive Officer, Oyster Therapeutics
What Oyster Therapeutics does
Oyster works on targeted protein degradation, an approach in which a drug steers the cell's own waste-disposal system towards a chosen protein so that it is broken down. The company says most degraders developed so far are large molecules that have trouble getting into the brain, which limits their use against neurological diseases such as Alzheimer's and Parkinson's.
Its SELFTAC platform is meant to get around that size problem. According to CE-Ventures, the platform lets smaller components pass through biological membranes and then assemble themselves into a working degrader, with the aim of making the drugs available as pills and able to reach the central nervous system.
The lead programme is a small oral degrader aimed at tau. An abnormal build-up of tau is the defining feature of a group of conditions called tauopathies, of which Alzheimer's is the best known. Oyster says its molecule is designed to clear the disease-related forms of tau while leaving healthy tau in place. The company argues that a pill suits diseases with very large patient numbers because it is easier to take, can be stored at room temperature and is cheaper to manufacture. The programme has not yet been tested in people.
Who invested
4BIO Capital is a venture firm that specialises in biotech. Owen Smith, a partner at the firm, said Oyster was taking on some of the hardest problems in medicine with a clear scientific basis, and acknowledged that much still has to be shown in clinical trials.
CE-Ventures, the corporate venture arm of Crescent Enterprises, which is based in Sharjah in the United Arab Emirates, said in its own announcement that the deal extends its life sciences portfolio into neuroscience and protein degradation. It did not say how much it put in. Tushar Singhvi, deputy chief executive and head of investments at Crescent Enterprises, said the firm backs technologies aimed at areas of significant unmet medical need.
Pharmaceutical Technology led its coverage with Lilly's participation, describing Oyster as Lilly-backed.
What the money is for
Oyster will use the money to take its tau degrader into clinical development and to keep building the SELFTAC platform, from which it expects to draw further drug candidates for diseases of the central nervous system.
Alongside the round, the company signed a sponsored research agreement with Massachusetts General Hospital. The work is supervised by Dr Catarina Silva, an investigator at the Mass General Brigham Neuroscience Institute and an assistant professor of neurology at Harvard Medical School. It gives Oyster access to neuronal cell lines derived from patients and to methods for producing and detecting oligomeric tau, a form of the protein that is toxic to nerve cells.
Chief executive Rob Johnson said the company wants to make protein-degrading medicines that reliably reach the brain and can be taken orally, and that its goal is to build the leading company in this area of neuroscience.
Company website: oyster-tx.com
